1. Home
  2. AKTX vs SIDU Comparison

AKTX vs SIDU Comparison

Compare AKTX & SIDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • SIDU
  • Stock Information
  • Founded
  • AKTX N/A
  • SIDU 2012
  • Country
  • AKTX United States
  • SIDU United States
  • Employees
  • AKTX N/A
  • SIDU N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • SIDU Telecommunications Equipment
  • Sector
  • AKTX Health Care
  • SIDU Telecommunications
  • Exchange
  • AKTX Nasdaq
  • SIDU Nasdaq
  • Market Cap
  • AKTX 35.7M
  • SIDU 30.0M
  • IPO Year
  • AKTX N/A
  • SIDU 2021
  • Fundamental
  • Price
  • AKTX $1.12
  • SIDU $2.02
  • Analyst Decision
  • AKTX Strong Buy
  • SIDU
  • Analyst Count
  • AKTX 1
  • SIDU 0
  • Target Price
  • AKTX $5.00
  • SIDU N/A
  • AVG Volume (30 Days)
  • AKTX 20.9K
  • SIDU 562.7K
  • Earning Date
  • AKTX 08-18-2025
  • SIDU 08-18-2025
  • Dividend Yield
  • AKTX N/A
  • SIDU N/A
  • EPS Growth
  • AKTX N/A
  • SIDU N/A
  • EPS
  • AKTX N/A
  • SIDU N/A
  • Revenue
  • AKTX N/A
  • SIDU $3,860,985.00
  • Revenue This Year
  • AKTX N/A
  • SIDU $144.49
  • Revenue Next Year
  • AKTX N/A
  • SIDU N/A
  • P/E Ratio
  • AKTX N/A
  • SIDU N/A
  • Revenue Growth
  • AKTX N/A
  • SIDU N/A
  • 52 Week Low
  • AKTX $0.85
  • SIDU $1.14
  • 52 Week High
  • AKTX $4.40
  • SIDU $7.65
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 44.73
  • SIDU 62.73
  • Support Level
  • AKTX $1.08
  • SIDU $1.88
  • Resistance Level
  • AKTX $1.15
  • SIDU $2.19
  • Average True Range (ATR)
  • AKTX 0.03
  • SIDU 0.13
  • MACD
  • AKTX 0.00
  • SIDU 0.01
  • Stochastic Oscillator
  • AKTX 57.14
  • SIDU 66.80

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About SIDU Sidus Space Inc.

Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.

Share on Social Networks: